NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study.

doi:10.1007/s00125-009-1608-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study.

Diabetologia - 1 Mar 2010

Chu A Y, Coresh J, Arking D E, Pankow J S, Tomaselli G F, Chakravarti A, Post W S, Spooner P H, Boerwinkle E, Kao W H L

Abstract excerpt

AIMS/HYPOTHESIS: To validate the reported association between rs10494366 in NOS1AP (the gene encoding nitric oxide synthase-1 adaptor protein) and the incidence of type 2 diabetes in calcium channel blocker (CCB) users and to identify additional NOS1AP variants associated with type 2 diabetes risk. METHODS: Data from 9 years of follow-up in 9,221 middle-aged white and 2,724 African-American adults free of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Black or African American

Share to Black People

Share to Blood Glucose

Share to Calcium Channel Blockers

Share to Calcium Channels

Share to Electrocardiography

Share to Risk

Source

Open in PubMed Open full text

Identifiers

PMID: 19943157
DOI: 10.1007/s00125-009-1608-0
PMCID: PMC3039128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study.PMID 19943157Read ↗

Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.Semantic proximity Read ↗

A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers.Semantic proximity Read ↗

Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study.Semantic proximity Read ↗

Serum calcium and incident type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study.Semantic proximity Read ↗

Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population.Semantic proximity Read ↗

NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with SchizophreniaSemantic proximity Read ↗

A common variant of NOS1AP is associated with QT interval duration in a Chinese population with Type 2 diabetes.Semantic proximity Read ↗

Associations between NOS1AP single nucleotide polymorphisms (SNPs) and QT interval duration in four racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis (MESA).Semantic proximity Read ↗

Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease.Semantic proximity Read ↗

Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations.Semantic proximity Read ↗

Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation.Semantic proximity Read ↗

NOS3 polymorphisms are associated with arterial stiffness in children with type 1 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.